PMID- 23627540
OWN - NLM
STAT- MEDLINE
DCOM- 20140724
LR  - 20181202
IS  - 1365-2230 (Electronic)
IS  - 0307-6938 (Linking)
VI  - 38
IP  - 8
DP  - 2013 Dec
TI  - Imiquimod 5% cream versus timolol 0.5% ophthalmic solution for treating 
      superficial proliferating infantile haemangiomas: a retrospective study.
PG  - 845-50
LID - 10.1111/ced.12150 [doi]
AB  - BACKGROUND: Infantile haemangiomas (IHs) are the most common vascular tumours of 
      infancy. Topical therapies are a possible treatment for superficial IHs. AIM: To 
      determine the efficacy and safety of topical therapy in the treatment of 
      superficial proliferating IHs. METHODS: The medical records of all the patients 
      with proliferating superficial IHs were reviewed. All lesions had been treated 
      either with imiquimod 5% cream or timolol 0.5% ophthalmic solution. Lesions were 
      classified into pairs, with one of each treatment in each pair, matched by 
      anatomical location, colour and size. A visual analogue scale (VAS) and the 
      Haemangioma Activity Score (HAS) were used to evaluate the efficacy of the two 
      drugs. The paired Student t-test was used to test for differences in recovery 
      with these two treatments. RESULTS: In total, 51 patients treated with timolol 
      and 94 treated with imiquimod met the inclusion criteria, and 20 lesions treated 
      with timolol were successfully matched to a lesion treated with imiquimod. The 
      paired t-test indicated that there was no significant difference in either VAS 
      score (P = 0.11) or HAS (P = 0.49). For the imiquimod-treated patients, crusting 
      was the most common reaction (65.0%, 13/20). This did not cause any superficial 
      scarring or skin pigmentation in the matched pairs; however, superficial scars 
      (14.9%, 14/94) and skin pigmentation disorders (28.7%, 27/94) were reported for 
      some of the unmatched cases. There were no adverse events (AEs) during the 
      treatment with timolol. CONCLUSIONS: Both imiquimod 5% cream or timolol 0.5% 
      ophthalmic solution showed equivalent clinical efficacy after 4 months of 
      treatment. Timolol appeared to have fewer AEs than imiquimod in the management of 
      superficial IHs. Larger, prospective controlled trials with long-term treatment 
      are needed to confirm these results.
CI  - (c) 2013 British Association of Dermatologists.
FAU - Qiu, Y
AU  - Qiu Y
AD  - Department of Plastic and Reconstructive Surgery, Shanghai Ninth People's 
      Hospital, Shanghai Jiao Tong University School of Medicine, PR, China.
FAU - Ma, G
AU  - Ma G
FAU - Yang, J
AU  - Yang J
FAU - Hu, X
AU  - Hu X
FAU - Chen, H
AU  - Chen H
FAU - Jin, Y
AU  - Jin Y
FAU - Lin, X
AU  - Lin X
LA  - eng
PT  - Journal Article
DEP - 20130430
PL  - England
TA  - Clin Exp Dermatol
JT  - Clinical and experimental dermatology
JID - 7606847
RN  - 0 (Adrenergic beta-Antagonists)
RN  - 0 (Aminoquinolines)
RN  - 0 (Antineoplastic Agents)
RN  - 817W3C6175 (Timolol)
RN  - P1QW714R7M (Imiquimod)
SB  - IM
MH  - Administration, Topical
MH  - Adrenergic beta-Antagonists/*administration & dosage
MH  - Aminoquinolines/*administration & dosage
MH  - Antineoplastic Agents/*administration & dosage
MH  - Female
MH  - Hemangioma/*drug therapy/pathology
MH  - Humans
MH  - Imiquimod
MH  - Infant
MH  - Male
MH  - Retrospective Studies
MH  - Skin Neoplasms/*drug therapy/pathology
MH  - Timolol/*administration & dosage
EDAT- 2013/05/01 06:00
MHDA- 2014/07/25 06:00
CRDT- 2013/05/01 06:00
PHST- 2013/01/03 00:00 [accepted]
PHST- 2013/05/01 06:00 [entrez]
PHST- 2013/05/01 06:00 [pubmed]
PHST- 2014/07/25 06:00 [medline]
AID - 10.1111/ced.12150 [doi]
PST - ppublish
SO  - Clin Exp Dermatol. 2013 Dec;38(8):845-50. doi: 10.1111/ced.12150. Epub 2013 Apr 
      30.